9GNX

Human SENP5 in complex with SUMO1 (E67D)

Summary for 9GNX

• Entry DOI: 10.2210/pdb9gnx/pdb
• Descriptor: Sentrin-specific protease 5, Small ubiquitin-related modifier 1 (3 entities in total)
• Functional Keywords: senp, ulp, sumo, hydrolase
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 2
• Total formula weight: 33675.87

Authors

Reverter, D.,Sanchez-Alba, L.,Maletic, M.,Mulder, M. (deposition date: 2024-09-04, release date: 2025-07-16)

Primary citation

Sanchez-Alba, L.,Ying, L.,Maletic, M.D.,De Bolos, A.,Borras-Gas, H.,Liu, B.,Varejao, N.,Amador, V.,Mulder, M.P.C.,Reverter, D.
Structural basis for the human SENP5's SUMO isoform discrimination.
Nat Commun, 16:4764-4764, 2025

PubMed Abstract: Post-translational SUMO modification is a widespread mechanism for regulating protein function within cells. In humans, SUMO-conjugated proteins are partially regulated by the deconjugating activity of six SENP family members. The proteolytic activity of these enzymes resides within a conserved catalytic domain that exhibits specificity for the two primary SUMO isoforms: SUMO1 and SUMO2/3. SENP5, along with SENP3, are nucleolar proteins involved in ribosome biogenesis and preferentially target SUMO2/3 isoforms. Here, we present the crystal structures of human SENP5 in complex with both SUMO1 and SUMO2 isoforms. These structures reveal a minimal complex interface and elucidate the molecular basis for SENP5's preference for the SUMO2 isoform. This preference can be attributed to a basic patch surrounding SENP5 Arg624 at the interface. Swapping mutagenesis and structural analysis demonstrate that Arg624 is favorably oriented to interact with Asp63 in SUMO2/3, while its interaction with the equivalent Glu67 in SUMO1 is less favorable. These results suggest that subtle structural differences within SUMO isoforms can significantly influence their deconjugation by SENP enzymes, opening new avenues for exploring the regulation of SUMOylation in various cellular processes and for developing therapeutic agents targeting SUMOylation pathways.

PubMed: 40404649
DOI: 10.1038/s41467-025-60029-4

Experimental method

X-RAY DIFFRACTION (1.9 Å)